Nivolumab (trade name: Opdivo) has been approved since June 2015 for adults with advanced melanoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.
Scientific Publications
Informed Melanoma Patients More Receptive to Internet Interventions
The melanoma patients receptive to an Internet-delivered behavioral intervention to promote skin self-examination (SSE) and sun protection behaviors may already have higher knowledge of melanoma signs, according to a research letter published in JAMA Dermatology.
UPDATE: Newlink Genetics Highlights New Study on Indoximod Showing Key Role of IDO in Local, Systemic Immunosuppression
NewLink Genetics Corporation NLNK, a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer, announced today that a peer-reviewed article in Cell Reports offers new insight demonstrating that the tumor indoleamine 2,3-dioxygenase (IDO) pathway is a central regulator of both local and systemic immunosuppression and resistance to immunotherapy in melanoma.
Antioxidants May Be Harmful in Patients With Melanoma
Antioxidants may double the rate of metastasis in malignant melanoma, a study published in the journal Science Translational Medicine has shown.